Therapy-Specific Considerations III
This session provides instruction on the clinical data and practical considerations for lutetium Lu 177 dotatate treatment.
Topic:
- Therapy-Specific Considerations for Lu-DOTATATE - Hyun Kim, MD
Target Audience
This activity is designed to meet the interests of radiation oncologists, radiation physicists, radiation therapists and radiation oncology residents.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Discuss the clinical data supporting the use of lutathera therapy in neuroendocrine tumors.
- Discuss practical considerations for delivery of lutathera.
- Hyun Kim, MD, is employed by Washington University School of Medicine in St. Louis. Dr. Kim receives grant/research funding from Varian and ViewRay. Dr. Kim receives compensation from Novartis. Dr. Kim is the Founder/CEO of GlobalART. Dr. Kim is Associate Editor of IJROBP.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.